Skip to search formSkip to main contentSkip to account menu

roxifiban

National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

AmidinesIsoxazoles

Narrower (1)

Lumaxis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans
The effect of platelet glycoprotein IIb/IIIa antagonists on the dynamics of platelet/fibrin clot formation and strength was… 
2003
2003
The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease
Introduction: Intravenous platelet glycoprotein (GP) IIb/IIIa receptor inhibitors have a significant beneficial impact on the… 
2003
2003
Effects of the glycoprotein IIb/IIIa antagonist Roxifiban on P-selectin expression, fibrinogen binding, and microaggregate formation in a phase I dose-finding study: no evidence for platelet…
The hypothesis that glycoprotein (GP) IIb/IIIa antagonists stimulate platelets is controversial. Here, we report the results of… 
2002
2002
Polymorphism of roxifiban.
Roxifiban was found to exist in two polymorphic forms. The polymorphs were detected by X-ray powder diffraction and solid-state… 
2002
2002
Comparative Efficacy Between the Glycoprotein IIb/IIIa Antagonists Roxifiban and Orbofiban in Inhibiting Platelet Responses in Flow Models of Thrombosis
This study was undertaken to compare the platelet binding characteristics and anti-platelet efficacy of a nonpeptide glycoprotein… 
2001
2001
Application of sorption--desorption moisture transfer modeling to the study of chemical stability of a moisture sensitive drug product in different packaging configurations.
2000
2000
Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
2000
2000
Mass spectrometric and NMR characterization of metabolites of roxifiban, a potent and selective antagonist of the platelet glycoprotein IIb/IIIa receptor
1. The methylester prodrug roxifiban is an orally active, potent and selective antagonist of the platelet glycoprotein GPIIb/IIIa… 
1999
1999
Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459.
Currently used antiplatelet drugs, including aspirin, ticlopidine, and others, are effective against certain but not all of the… 
1999
1999
Optimization and validation of chiral high-performance liquid chromatographic method for analysis of a fibrinogen (gpIIb/IIIa) receptor antagonist.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)